FIG 6.

Cumulative incidence of pelvic or para-aortic recurrence (competing event is death before recurrence of interest). Three competing risk analyses were carried out for three different types of recurrences: any vaginal, any pelvic or any para-aortic nodes, and any distant. More than one recurrence type could be reported for each patient. Death before a specific type of recurrence was considered a competing event. There was a significant differential in the cumulative incidence of pelvic or para-aortic node recurrences between the treatment arms (hazard ratio [HR] of radiation therapy [RT] relative to vaginal cuff brachytherapy plus chemotherapy [VCB/C], 0.472; 95% CI, 0.24 to 0.94). The 52-month cumulative incidence proportion of these types of recurrences was 0.044 for the RT arm and 0.092 for the VCB/C arm. There were no differences in the incidence of vaginal or distant recurrences between the two treatment arms. Approximately 2.5% and 18% of patients will have a vaginal or distant recurrence, respectively, within 5 years of treatment.